Company Overview and News

0
Coffee Day Enterprises Q4 profit rises 36% at Rs34.5 crore

2018-05-17 livemint
New Delhi: Coffee Day Enterprises, which runs coffee chain under brand name Cafe Coffee Day, on Thursday reported a 36.36% rise in consolidated net profit at Rs34.5 crore for the quarter ended March 2018.
539436 COFFEEDAY

0
Coffee Day Enterprises Q4 net up 36% at Rs 34.5 cr

2018-05-17 moneycontrol
Coffee Day Enterprises, which runs coffee chain under brand name Cafe Coffee Day, today reported a 36.36 percent rise in consolidated net profit at Rs 34.5 crore for the quarter ended March 2018.
539436 COFFEEDAY

0
Coffee Day Enterprises Limited - Financial Result Updates

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539436 COFFEEDAY

0
Coffee Day Enterprises Limited - Investor Presentation

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539436 COFFEEDAY

0
Mindtree investor V.G. Siddhartha sees firm doubling revenue by 2023

2018-05-02 livemint
Bengaluru: V. G. Siddhartha, the founder of Café Coffee Day Ltd who holds a fifth of the equity in Mindtree Ltd, said he remains committed to the information technology (IT) outsourcing company, which according to him is expected to more than double its revenue to $2 billion by 2023.
539436 COFFEEDAY MNDQY

0
Chai Point parent in talks to raise $20 million from Paragon, others

2018-04-08 livemint
Bengaluru: Mountain Trails Foods Pvt. Ltd, which owns the Chai Point chain of tea and snacks stores, is in advanced discussions to raise about $20 million in Series C funding from new investors such as private equity firm Paragon Partners and existing investors that include Saama Capital India Advisors Llp, according to two people familiar with the talks.
539436 COFFEEDAY

0
Coffee Day Enterprises Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539436 COFFEEDAY

27
News Live: PE investments in Jan-Feb touch $2.3bn, says Grant Thornton

2018-03-21 moneycontrol
Private equity investments witnessed a two-fold jump in February with transactions worth $1.3 billion taking the deal tally for the first two months of this year to $2.3 billion, tax and advisory firm Grant Thornton said. There were 62 PE deals worth $1,330 million, while in the corresponding period last year there were 45 such transactions worth $588 million. (PTI)
RIO RIO 539436 532715 SADBHIN 533573 532712 BHRQY 533278 GITANJALI RTPPF RCOM RTNTF 500477 BHARTIARTL CLNDY ASHOKLEY COFFEEDAY 539346 AKLD 532454 GTJLY APLLTD RIO AKLS COALINDIA

56
News Live: Fat finger wipes $3bn off Taiwan oil heavyweight

2018-03-21 moneycontrol
British superbike maker Triumph Motorcycles has launched the all-new TIGER 800 XCX and XR line-ups in India priced between Rs 11.76 lakh and Rs 13.76 lakh.
RIO RIO 539436 COFFEEDAY 532715 539346 SADBHIN 533573 532712 BHRQY AKLD GITANJALI BRK.A 532454 GTJLY APLLTD RTPPF RCOM RIO RTNTF 500477 BHARTIARTL AKLS ASHOKLEY

0
Mindtree: Coffee Day in dealwith Siddhartha

2018-03-20 thehindubusinessline
Our Bureau Coffee Day Enterprises on Tuesday said that it has entered into an agreement with VG Siddhartha, who owns 3.34 per cent stake or 54.69 lakh shares in Mindtree. Accordingly, Siddhartha will vote alongside Coffee Day Enterprises while the title and ownership of Mindtree shares will belong exclusively to Siddhartha.
539436 COFFEEDAY GSPL 532702

0
Coffee Day Enterprises Limited - Acquisition

2018-03-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539436 COFFEEDAY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...